Vanguard Investments Australia
CGEM icon

Vanguard Investments Australia’s Cullinan Oncology CGEM Stock Holding History

Vanguard Investments Australia’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$132K Hold
7,272
– – ﹤0.01% 2252
2026
Q1 		$103K Buy
+7,272
New +$93.5K ﹤0.01% 2268

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Vanguard Investments Australia's CGEM Position: Q2 2026 in Review

Vanguard Investments Australia held its Cullinan Oncology (CGEM) position steady in Q2 2026 at 7,272 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #2252.

Vanguard Investments Australia first reported a position in CGEM in Q1 2026 and has held it in 2 quarters since. 167 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Vanguard Investments Australia held 7,272 shares of Cullinan Oncology worth $132K as of Q2 2026.
  • Vanguard Investments Australia left its Cullinan Oncology share count unchanged in Q2 2026.
  • Cullinan Oncology made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2252 holding.
  • Vanguard Investments Australia first reported a position in Cullinan Oncology in Q1 2026 and has held it in 2 quarters since.
  • 167 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.